The World Needs an AIDS Vaccine

Our Mission
The International AIDS Vaccine Initiative (IAVI) is a global nonprofit that accelerates development of broadly effective AIDS vaccines and other biomedical prevention tools. Antiretroviral treatment, which has dramatically altered the course of the epidemic, now keeps 18 million people living with HIV alive. More than two million people newly acquire the virus each year, but fewer than half have access to treatment. Only a vaccine has the potential to end AIDS.

Our Work
The International AIDS Vaccine Initiative is:

A catalyst: IAVI’s product development capabilities encompass design to clinical evaluation, which enables HIV vaccine research to operate with greater efficiency. IAVI seeks to share knowledge and implement discoveries from the range of advanced scientific inquiries to design better, more effective next generation candidates, as vaccine design is an iterative process.

Innovative: An unyielding commitment to responding quickly to advances in the science and fast-tracking the most promising ideas accelerates the translation of innovative concepts into high-potential candidates for clinical testing.

Collaborative: Our unique research model pioneers inventive approaches to collaboration, sharing scientific knowledge across sectors, and amplifying cutting-edge research expertise from U.S. institutions – including more than 50 U.S. academic, government, and industry allies – and partners around the world.

Building capacity: IAVI leverages deeply rooted research partnerships in AIDS-affected communities across Africa and India to better understand their needs and ensure that a vaccine can and will be used by the people who need it most. HIV prevention R&D supports scientific leadership in these regions and strengthens their health system infrastructure, decreasing their future reliance on foreign aid.

Our Impact
Contributions by IAVI and its partners have led to:

Groundbreaking discoveries: In 2009 scientists in Seattle isolated antibodies preventing infection across multiple HIV strains, originating from blood samples collected from African volunteers. IAVI’s pioneering Neutralizing Antibody Center in La Jolla, California, seeks to understand how these antibodies could work in a vaccine.

Greater health security: Partnering with the US Agency for International Development (USAID), IAVI prepares high-risk communities for future vaccine clinical trials in Africa and India. Together we train local scientists and build critically needed health systems, which ensure a swifter, more coordinated global response to AIDS and other epidemics.

Pandemic preparedness: Researchers at IAVI’s Design and Development Lab in Brooklyn are assessing the viability of an HIV vaccine built on the same platform as the Ebola vaccine. This type of translational science is gaining recognition for its potential to hasten production of vaccines for other infectious diseases.

“From its start in 1996, IAVI revolutionized the way the world thinks about vaccine development, merging the best attributes of the public and private sectors to overcome one of the most serious health threats of our times. IAVI is small, entrepreneurial and focused... We’re proud to be supporting the pioneering work of IAVI and urge you to join us in the development of an AIDS vaccine.”

–Bill Gates
IAVI gratefully acknowledges the generous support provided by the following major donors

IAVI gratefully acknowledges the generous support provided by the following major donors


And many other generous individuals from around the world

As of January 2017